In this program expert panelists will discuss these issues using trial data, clinical experience and case examples to demonstrate the benefits of moving to TAVR as the primary treatment option for low-risk AS patients.
This webcast discussion will move beyond high-risk patients and explore the new boundaries of transcatheter therapy. Participants will learn from discussions about considerations for low-risk patient populations, treatment decision making, and recent clinical trial data.
This program will provide comprehensive overview of recent clinical trials and practical implications, case-based review of MR treatment options, and discussion of approaches for selecting appropriate surgical or transcatheter MR therapies.
This webcast provides comprehensive discussion of TAVR as continued progress is seen in patients with low surgical risk. Emphasis is placed on approaches to integrating quality of life (QOL) metrics into pre-procedural planning, and utilizing scores for effective quantification of long-term outcomes in low-risk TAVR patients.
This brief panel discussion touches upon expert-recommended approaches to such challenges- high case volume, patient education, care coordination- as well as other considerations for achieving excellence in heart team performance and patient outcomes in TAVR.
This enduring activity will discuss emerging clinical science pertaining to TAVR use in low-risk patient populations, considerations for integrating new TAVR knowledge into practice, and the shifting roles of transcatheter (TAVR) and surgical replacement (SAVR) as new clinical knowledge in these areas continues to emerge.